Organisation: Azactam

A COMPREHENSIVE SERIES OF ARTICLES ON THIS TOPIC

Elan to cut spending by $100m

ELAN is to cut spending by $100m (€77m) this year, reducing cash-burn to $250m.

Fri, 29 Apr, 2005

Only way is down for Elan

Elan chief executive Kelly Martin’s contract includes $5m if Elan is sold this year and $3m if it goes next year, adding to doubts about the company’s survival after the announcement of a third patient death. BRIAN O'MAHONY reports.

Sat, 02 Apr, 2005

Elan takes action against Pfizer

ELAN said it is seeking binding arbitration with American pharmaceutical giant Pfizer over research into a potential treatment for Alzheimer’s disease.

Sat, 13 Dec, 2003

Elan to retain drug delivery and acute care business

Elan corporation has announced it is retaining NanoSystems, its drug delivery business based in Pennsylvania, its drug delivery business and operations in Georgia, and its acute care business, which includes hospital products Maxipime and Azactam.

Fri, 12 Dec, 2003

Elan puts anti-infective drugs on sale

EMBATTLED pharmaceutical firm Elan Corp has put its three anti-infective drugs up for sale but is unlikely to conclude a deal before the end of the year, sources close to the situation are saying.

Fri, 09 Aug, 2002